Safety alerts issued by regulatory authorities: usefulness of meta-analysis in predicting
earlier risks
Carlos Alves1,2,3, Francisco Batel Marques1,2, Ana Filipa Macedo3
1. Portuguese Central Regional Pharmacovigilance Unit (UFC), Centre for Health Technology
Assessment and Drug Research, AIBILI, Coimbra, Portugal.
2. School of Pharmacy, University of Coimbra, Coimbra, Portugal.
3. Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.
Carlos Alves: PharmD. PhD candidate at School of Pharmacy, University of Coimbra, Coimbra,
Portugal, and at CICS-UBI – Health Sciences Research Centre, University of Beira Interior,
Covilhã, Portugal. Assistant Investigator at Centre for Health Technology Assessment and Drug
Research (CHAD), AIBILI, Coimbra, Portugal; Ana F. Macedo: PharmD, PhD. Research
Fellow at Faculty of Health Sciences, University of Beira Interior, Covilhã, Portugal; Francisco
Batel-Marques: PharmD, PhD. Professor at School of Pharmacy, University of Coimbra,
Coimbra, Portugal. Director of Centre for Health Technology Assessment and Drug Research
(CHAD), AIBILI, Coimbra, Portugal
Corresponding author:
Carlos Miguel Costa Alves
Central Portugal Regional Pharmacovigilance Unit (UFC), Centre for Health Technology
Assessment and Drug Research (CHAD)
AIBILI – Association for Innovation and Biomedical Research on Light and Image
Azinhaga de Santa Comba, Celas
3000-548 Coimbra, PORTUGAL
E-mail: carlosmiguel.costaalves@gmail.com
Telephone number: (+351) 239 480 100
Fax number: (+351) 239 480 117
Supplemental File 1 – References from studies presented at Table 1
w1. Diav-Citrin O, Shechtman S, Weinbaum D, et al (2008) Paroxetine and fluoxetine in
pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol.
66(5): 695-705
w2. Eli Lilly and Company Clinical Trial Registry (2013) Results Observational/Noninterventional
studies.
Available
at:
http://www.lillytrials.com/nonintstudies/result_files/13947.pdf. Accessed 22 May 2013.
w3. Chambers CD, Johnson KA, Dick LM, et al (1996). Birth outcomes in pregnant women
taking fluoxetine. N Engl J Med. 335(14):1010-5.
w4. Malm H, Klaukka T, Neuvonen PJ (2005). Risks associated with selective serotonin
reuptake inhibitors in pregnancy. Obstet Gynecol. 106(6):1289-96.
w5. Källén BA, Otterblad Olausson P (2007). Maternal use of selective serotonin re-uptake
inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin
Mol Teratol. 79(4):301-8.
w6. Alwan S, Reefhuis J, Rasmussen SA, et al (2007). Use of selective serotonin-reuptake
inhibitors in pregnancy and the risk of birth defects. N Engl J Med. 356(26):2684-92.
w7. Louik C, Lin AE, Werler MM, Hernández-Díaz S, Mitchell AA (2007). First-trimester use
of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med.
356(26):2675-83.
w8. Oberlander TF, Warburton W, Misri S, et al (2008). Major congenital malformations
following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using
population-based health data. Birth Defects Res B Dev Reprod Toxicol. 83(1):68-76.
w9. Vestergaard P, Rejnmark L, Mosekilde L (2006) Proton pump inhibitors, histamine H2
receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int.
79(2):76-83.
w10. Yang YX, Lewis JD, Epstein S, Metz DC (2006) Long-term proton pump inhibitor
therapy and risk of hip fracture. JAMA. 296(24):2947-2953.
w11. Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD (2008) Use of proton
pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 179(4):319-326.
w12. Corley DA, Kubo A, Zhao W, Quesenberry C (2010) Proton pump inhibitors and
histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
Gastroenterology. 139(1):93-101.
w13. Gray SL, LaCroix AZ, Larson J, et al (2010) Proton pump inhibitor use, hip fracture, and
change in bone mineral density in postmenopausal women. Arch Intern Med. 170(9):765-771.
w14. Yu EW, Blackwell T, Ensrud KE, et al (2008) Acid-suppressive medications and risk of
bone loss and fracture in older adults. Calcif Tissue Int. 83(4):251-259.
w15. Kaye JA, Jick H (2008) Proton pump inhibitor use and risk of hip fractures in patients
without major risk factors. Pharmacotherapy 28(8):951-959.
w16. Targownik LE, Lix LM, Leung S, Leslie WD (2010) Proton-pump inhibitor use is not
associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology.
138(3):896-904.
w17. de Vries F, Cooper AL, Cockle SM, van Staa TP, Cooper C (2009) Fracture risk in
patients receiving acidsuppressant medication alone and in combination with bisphosphonates.
Osteoporos Int. 20(12):1989-1998.
w18. Roux C, Briot K, Gossec L, et al (2009) Increase in vertebral fracture risk in
postmenopausal women using omeprazole. Calcif Tissue Int. 84(1): 13-19.
w19. Kwok CS, Yeong JK, Loke YK (2011) Meta-analysis: risk of fractures with acidsuppressing medication. Bone. 48(4):768-776.
w20. Eom CS, Park SM, Myung SK, Yun JM, Ahn JS (2011) Use of acid-suppressive drugs
and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 9(3):257-267.
w21. Pouwels S, Lalmohamed A, Souverein P, et al (2011). Use of proton pump inhibitors and
risk of hip/femur fracture: a population-based case-control study. Osteoporos Int. 22(3):903-10.
w22. Chiu HF, Huang YW, Chang CC, Yang CY (2010). Use of proton pump inhibitors
increased the risk of hip fracture: a population-based case-control study. Pharmacoepidemiol
Drug Saf. 19(11):1131-6.
w23. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensin-receptor
blockade and risk of cancer: meta-analysis of randomised controlled trials. The Lancet
Oncology. 11(7):627-636.
w24. Bangalore S, Kumar S, Kjeldsen SE, et al (2011) Antihypertensive drugs and risk of
cancer: network meta-analyses and trial sequential analyses of 324,168 participants from
randomized trials. Lancet Oncol. 12(1):65-82.
w25. The ARB Trialists Collaboration (2011) Effects of telmisartan, irbesartan, valsartan, and
candesartan, and losartan on cancers in 15 trials. J Hypertens. 29(4):623-635.
w26. Pasternak B, Svanström H, Callréus T, Melbye M, Hviid A (2011) Use of angiotensin
receptor blockers and the risk of cancer. Circulation. 123(16):1729-1736.
w27. The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint
Trial (ONTARGET) Investigators (2008). Telmisartan, ramipril, or both in patients at high risk
for vascular events. N Engl J Med 358 :1547–1559.
w28. The Telmisartan Randomized Assessment Study in ACEi Intolerant Subjects with
Cardiovascular Disease (TRANSCEND) Investigators (2008). Effects of the angiotensin
receptor blocker, telmisartan on cardiovascular events in high-risk patients intolerant to ACEinhibitors: a randomized controlled trial. Lancet 372 :1174–1183
w29. Yusuf S, Diener H-C, Sacco RL, Cotton D, Ounpuu S, Lawton WA, et al., for the
PRoFESS Study Group (2008). Telmisartan to prevent recurrent stroke and cardiovascular
events. N Engl J Med 359:1225–1237.
w30. The Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research
(NAVIGATOR) Study Group (2010). Effect of valsartan on the incidence of diabetes and
cardiovascular events. N Engl J Med 362:1477–1490.
w31. Julius S, Kjeldsen E, Weber M, Brunner HR, Ekman S, Hansson L, et al (2004).
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on
valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation trial
(VALUE) randomized trial. Lancet 363:2022–2031.
w32. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, et al
(2003). Effects of candesartan on mortality and morbidity in patients with chronic heart failure:
the CHARM-Overall programme. Lancet 362:759–766.
w33. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al (2003). The
Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized
double-blind intervention trial. J Hypertens 21:875–886.
w34. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P (2001).
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2
diabetes. N Engl J Med 345:870–78.
w35. Brenner BM, Cooper ME, de Zeeuw D, et al (2001). Effects of losartan on renal and
cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med
345:861–69.
w36. Berl T, Hunsicker LG, Lewis JB, et al (2003). Cardiovascular outcomes in the Irbesartan
Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern
Med 138:542–49.
w37. Dahlöf B, Devereux RB, Kjeldsen SE, et al, for the LIFE study group (2002).
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in
hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:995–1003
w38. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O (2003).
Metabolic outcome during 1 year in newly detected hypertensives: results of the
Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation
(ALPINE study). J Hypertens 21:1563–74.
w39. Granger CB, McMurray JJV, Yusuf S, et al, for the CHARM Investigators and
Committees (2003). Effects of candesartan in patients with chronic heart failure and reduced
left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the
CHARM-Alternative trial. Lancet 362:772–76
w40. Pfeffer MA, McMurray JJ, Velazquez EJ, et al (2003). Valsartan, captopril, or both in
myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl
J Med 349:1893–906.
w41. Julius S, Nesbitt SD, Egan BM, et al (2006). Feasibility of treating prehypertension with
an angiotensin-receptor blocker. N Engl J Med 354:1685–97.
w42. Mochizuki S, Dahlöf B, Shimizu M, et al, for the Jikei Heart Study group (2007).
Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei
Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet
369:1431–39.
w43. Zile MR, Gaasch WH, Anand IS, et al (2010). Mode of death in patients with heart failure
and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved
Ejection Fraction Study (I-Preserve) trial. Circulation 121:1393–405.
w44. Disertori M, Latini R, Barlera S, et al (2009). Valsartan for prevention of recurrent atrial
fibrillation. N Engl J Med 360: 1606–17.
w45. Kasanuki H, Hagiwara N, Hosoda S, et al (2009). Angiotensin II receptor blocker-based
vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically
documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan
Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J
30:1203–12.
w46. Sawada T, Yamada H, Dahlof B, Matsubara H (2009). Effects of valsartan on morbidity
and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO
HEART Study. Eur Heart J 30: 2461–69.
w47. Cohn JN, Tognoni G (2001). A randomized trial of the angiotensin-receptor blocker
valsartan in chronic heart failure. N Engl J Med 345:1667–75.
w48. The ACTIVE I Investigators (2011). Irbesartan in patients with atrial fibrillation. N Engl
J Med. 364(10):928-38.
w49. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving H-H, et al (2008). Effect of
candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of
retinopathy in type 1 diabetes: randomized, placebo-controlled trials. Lancet 372:1394–1402.
w50. Sjolie AK, Klein R, Porta M, Orchard T, Parving H-H, Bilous R, et al (2008). Effect of
candesartan on progression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomized
placebo-controlled trial. Lancet 372:1385–1393.
w51. Dormandy JA, Charbonnel B, Eckland DJ, et al (2005) Secondary prevention of
macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective
pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet.
366(9493):1279-1289.
w52. Lewis JD, Ferrara A, Peng T, et al (2011) Risk of bladder cancer among diabetic patients
treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care.
34(4):916-922.
w53. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H (2012) Pioglitazone
and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
Diabetologia. 55(7):1953-1962.
w54. Azoulay L, Yin H, Filion KB, et al (2012) The use of pioglitazone and the risk of bladder
cancer in people with type 2 diabetes: nested case-control study. BMJ 344:e3645
doi:10.1136/bmj.e3645.
w55. Parkin L, Sharples K, Hernandez RK, Jick SS (2011) Risk of venous thromboembolism
in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control
study based on UK General Practice Research Database. BMJ doi:10.1136/bmj.d2139
w56. Jick SS, Hernandez RK (2011) Risk of non-fatal venous thromboembolism in women
using oral contraceptives containing drospirenone compared with women using oral
contraceptives containing levonorgestrel: case-control study using United States claims data.
BMJ. doi:10.1136/bmj.d2151.
w57. Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C (2009) Hormonal contraception and
risk of venous thromboembolism: national follow-up study. BMJ. doi:10.1136/bmj.b2890.
w58. Van Hylckama V, Helmerhorst FM, Vandenbroucke JP, Doggen CJM, Rosendaal FR
(2009) The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and
progestogen type: results of the MEGA case-control study. BMJ. doi:10.1136/bmj.b2921.
w59. Dinger JC, Heinemann LA, Kühl-Habich D (2007) The safety of a drospirenonecontaining oral contraceptive: final results from the European Active Surveillance Study on oral
contraceptives based on 142,475 women-years of observation. Contraception 75(5):344-354.
w60. Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM (2007) Risk of
thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.
Obstet Gynecol 110(3):587-593.
w61. Dinger J, Assmann A, Möhner S, Minh TD (2010) Risk of venous thromboembolism and
the use of dienogest- and drospirenone-containing oral contraceptives: results from a German
case-control study. J Fam Plann Reprod Health Care. 36(3):123-129.
w62. Ridker PM, Danielson E, Fonseca FA, et al (2008) Rosuvastatin to prevent vascular
events in men and women with elevated C-reactive protein. N Engl J Med. 359(21):2195-2207.
w63. Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk
of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360(9346):1623-1630.
w64. Sattar N, Preiss D, Murray HM, et al (2010) Statins and risk of incident diabetes: a
collaborative meta-analysis of randomised statin trials. Lancet. 375(9716):735-742.
w65. Freeman DJ, Norrie J, Sattar N, et al (2001) Pravastatin and the Development of Diabetes
Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary
Prevention Study. Circulation. 103(3):357-362.
w66. Kostapanos MS, Liamis GL, Milionis HJ, Elisaf MS (2010) Do statins beneficially or
adversely affect glucose homeostasis? Curr Vasc Pharmacol. 8(5):612-631.
w67. Sabatine MS, Wiviott SD, Morrow DA, McCabe CH, Cannon CP (2004) High-dose
atorvastatin associated with worse glycemic control: a PROVE-IT TIMI 22 substudy.
Circulation. 110(suppl I):S834.
w68. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM (2009)
Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care.
32(10):1924-1929.
w69. Sukhija R, Prayaga S, Marashdeh M, et al (2009) Effect of statins on fasting plasma
glucose in diabetic and nondiabetic patients. J Investig Med. 57(3):495-499.
w70. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK (2010) Atorvastatin causes insulin
resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol.
55(12):1209-1216.
w71. Thongtang N, Ai M, Otokozawa S, et al (2011) Effects of maximal atorvastatin and
rosuvastatin treatment on markers of glucose homeostasis and inflammation. Am J Cardiol.
107(3):387-392.
w72. Mills EJ, Wu P, Chong G, et al (2011) Efficacy and safety of statin treatment for
cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.
QJM. 104(2):109-124.
w73. Culver AL, Ockene IS, Balasubramanian R, et al (2012) Statin use and risk of diabetes
mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med.
172(2):144-152.
w74. Sever PS, Dahlof B, Poulter NR, et al (2003). Prevention of coronary and stroke events
with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol
concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm
(ASCOT-LLA): a multicenter randomized controlled trial. Lancet 361:1149-58.
w75. Collins R, Armitage J, Parish S, et al (2003). MRC/BHF Heart Protection Study of
cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebocontrolled trial. Lancet 361:2005-16.
w76. Freeman DJ, Norrie J, Sattar N, et al (2001). Pravastatin and the development of diabetes
mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention
Study. Circulation 103:357-62.
w77. Keech A, Colquhoun D, Best J, et al (2003).Secondary prevention of cardiovascular
events with long-term pravastatin in patients with diabetes or impaired fasting glucose – results
from LIPID trial. Diabetes Care 26:2713-21.
w78. Kjekshus J, Apetrei E, Barrios V, et al (2007). Rosuvastatin in older patients with systolic
heart failure. N Engl J Med 357:2248-61.
w79. Shepherd J, Blauw GJ, Murphy MB, et al (2002). Pravastatin in elderly individuals at risk
of vascular disease (PROSPER): a randomized controlled trial. Lancet 360:1623-30.
w80. Nakamura H, Arakawa K, Itakura H, et al (2006). Primary prevention of cardiovascular
disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial.
Lancet 368:1155-63.
w81. Dwons JR, Clearfield M, Weis S, et al (1998). Primary prevention of acute coronary
events with lovastatin in men and women with average cholesterol levels: results of
AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA
279:1615-22.
w82. Scandinavian Simvastatin Survival Study study group (1994). Randomised trial of
cholesterol lowering in 444 patients with coronary heart disease: the Scandinavian Simvastatin
Survival Study (4S). Lancet 344:1383-89.
w83. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (2002).
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to
pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT-LLT). JAMA 288:2998-3007.
w84. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza
nell’Infarto Miocardico) (2000). Results of the low-dose (20 mg) pravastatin GISSI Prevenzione
trial in 4271 patients with recente myocardial infarction: do stopped trials contribute to overall
knowledge? Ital Heart J 1:810-20.
w85. Tavazzi L, maggioni AP, Marchioli R, et al (2008). Effect of rosuvastatin in patients with
chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial.
Lancet 372:1231-39.
w86. Yokoi H, Nobuyoshi M, Mitsudo K, et al (2005). Three-year follow-up results of
angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of
obstructive multiple atheroma (ATHEROMA) study. Circ J 69:875-83.
w87. The Pravastatin Multinational Study Group for Cardiac Risk Patients (1993). Effects of
pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300
mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 72:1031-7.
w88. Al-Tureihi FIJ, Hassoun A, Wolf-Klein G, et al (2005) Albumin, length of stay, and
proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home
patients. J Am Med Dir Assoc. 6(2):105-108.
w89. Cunningham R, Dale B, Undy B, Isenberg H. (2003) Proton pump inhibitors as a risk
factor for Clostridium difficile diarrhoea. J Hosp Infect. (54):243-245.
w90. Dial S, Alrasadi K, Manoukian C, Huang A, Menzies D (2004) Risk of Clostridium
difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and casecontrol studies. CMAJ. 171(1):33-38.
w91. Dial S, Delaney JAC, Barkun A, Suissa S (2005) Use of gastric acid-suppressive agents
and the risk of community-acquired Clostridium difficile-associated disease. JAMA.
294(23):2989-2995.
w92. Muto C, Pokrywka M, Shutt K, et al (2005) A large outbreak of Clostridium difficile
associated disease with an unexpected proportion of deaths and colectomies at a teaching
hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol. 26(3):273280.
w93. Dial S, Delaney JA, Schneider V, Suissa S (2006) Proton pump inhibitor use and risk of
community-acquired Clostridium difficile-associated disease defined by prescription for oral
vancomycin therapy. CMAJ. 175(7):745-748.
w94. Dial S, Kezouh A, Dascal A, et al (2008) Patterns of antibiotic use and risk of hospital
admission for Clostridium difficile infection among elderly people in Quebec. CMAJ.
179(8):767-772.
w95. Akhtar AJ, Shaheen M (2007) Increasing incidence of Clostridium difficile-associated
diarrhea in African-American and Hispanic patients: association with the use of proton pump
inhibitor therapy. J Natl Med Assoc. 99(5):500-504.
w96. Aseeri M, Schroeder T, Kramer J, Zackula R (2008) Gastric acid suppression by proton
pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized
patients. Am J Gastroenterol. 103(9):2308-2313.
w97. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM (2007) Association of
proton-pump inhibitors with outcomes in Clostridium difficile colitis. Am J Health Syst Pharm.
64(22):2359-2363.
w98. Dalton BR, Lye-Maccannell T, Henderson EA, Maccannell DR, Louie TJ. (2009) Proton
pump inhibitors increase significantly the risk of Clostridium difficile infection in a lowendemicity, non-outbreak hospital setting. Aliment Pharmacol Ther. 29(6):626-634.
w99. Dubberke ER, Reske KA, Yan Y, Olsen MA, McDonald LC, Fraser VJ (2007)
Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk
factors. Clin Infect Dis. 45(12):1543-1549.
w100. Howell MD, Novack V, Grgurich P, et al (2010) Iatrogenic gastric acid suppression and
the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 170(9):784-790.
w101. Janarthanan S, Ditah I, Kutait A, et al (2010) A meta-analysis of 16 observational
studies on proton pump inhibitor use and risk of Clostridium difficile associated diarrhea. Am J
Gastroenterol 105(Suppl 1):S378
w102. Jayatilaka S, Shakov R, Eddi R, Bakaj G, Baddoura WJ, DeBari VA (2007) Clostridium
difficile infection in an urban medical center: five-year analysis of infection rates among adult
admissions and association with the use of proton pump inhibitors. Ann Clin Lab Sci.
37(3):241-247.
w103. Kazakova SV, Ware K, Baughman B, et al (2006) A hospital outbreak of diarrhea due to
an emerging epidemic strain of Clostridium difficile. Arch Intern Med. 166(22):2518-2524.
w104. Kim JW, Lee KL, Jeong JB, et al (2010) Proton pump inhibitors as a risk factor for
recurrence of Clostridium-difficile-associated diarrhea. World J Gastroenterol. 16(28):35733577.
w105. Leonard J, Marshall JK, Moayyedi P (2007) Systematic review of the risk of enteric
infection in patients taking acid suppression. Am J Gastroenterol. 102(9):2047-2056.
w106. Linsky A, Gupta K, Lawler EV, Fonda JR, Hermos JA (2010) Proton pump inhibitors
and risk for recurrent Clostridium difficile infection. Arch Intern Med. 170(9):772-778.
w107. Turco R, Martinelli M, Miele E, et al (2010) Proton pump inhibitors as a risk factor for
paediatric Clostridium difficile infection. Aliment Pharmacol Ther. 31(7):754-759.
w108. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC (2006) Proton
pump inhibitor therapy is a risk factor for Clostridium difficile-associated diarrhoea. Aliment
Pharmacol Ther. 24(4):613-9.
w109. Pepin J, Saheb N, Coulombe M-A, et al (2005) Emergence of fluoroquinolones as the
predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an
epidemic in Quebec. Clin Infect Dis. 41(9):1254-1260.
w110. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K (2000) Gastric acid suppression
does not promote clostridial diarrhoea in the elderly. QJM. 93(3):175-181.
w111. Loo VG, Poirier L, Miller MA, et al (2005) A predominantly clonal multi-institutional
outbreak of Clostridium diffcile-associated diarrhea with high morbidity and mortality. N Engl J
Med. 353:2442-2449.
w112. Beaulieu M, Williamson D, Pichette G, Lachaine J (2007) Risk of Clostridium difficile
associated disease among patients receiving proton-pump inhibitors in a Quebec medical
intensive care unit. Infect Control Hosp Epidemiol. 28(11):1305-1307.
w113. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN (2006) Proton pump
inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based
study. Clin Infect Dis. 43(10):1272-1276.
w114. Bajaj JS, Ananthakrishnan AN, Hafeezullah M, et al (2010). Clostridium difficile is
associated with poor outcomes in patients with cirrhosis: a national and tertiary center
perspective. Am J Gastroenterol 105:106-13.
w115. Debast SB, van Leengoed LA, Goorhuis A et al (2009). Clostridium difficile PCR
ribotype 078 toxinotype V found in diarrhoeal pigs identical to isolates from affected humans.
Environ Microbiol 11:505-11.
w116. Baxter R, Ray GT, Fireman BH (2008). Case-control study of antibiotic use and
subsequent Clostridium difficile-associated diarrhea in hospitalized patients. Infect Control
Hosp Epidemiol 29:44-50.
w117. Gillis C, Fardy J, Hutchinson J (2006). Proton pump inhibitors: Are they a risk factor for
Clostridium difficile diarrhea: A case-control study. Gastroenterol 20(Suppl A):1091.
w118. Loo VG, Poirier L, Miller MA, et al (2005). A predominantly clonal multi-institutional
outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl
J Med 353:2442-9.
w119. Modena S, Bearelly D, Swartz K, et al (2005). Clostridium difficile among hospitalized
patients receiving antibiotics: A case-control study. Infect Control Hosp Epidemiol 26:685-90.
w120. Kyne L, Sougioultzis S, McFarland LV, et al (2002). Underlying disease severity as a
major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol
23:653-9.
w121. Orsi A, Sherman O, Woldeselassie Z (2001) Simvastatin-associated memory loss.
Pharmacotherapy. 21(6):767-769.
w122. Parker BA, Polk DM, Rabdiya V, et al (2010) Changes in memory function and
neuronal activation associated with atorvastatin therapy. Pharmacotherapy. 30(6):236e-240e.
w123. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM (2003) Statin-associated
memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy.
23(7):871-880.
w124. Evans MA, Golomb BA (2009) Statin-associated adverse cognitive effects: survey
results from 171 patients. Pharmacotherapy. 29(7):800-811.
w125. Muldoon MF, Barger SD, Ryan CM, et al (2000) Effects of lovastatin on cognitive
function and psychological well-being. Am J Med. 108(7):538-546.
w126. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB (2004) Randomized trial of
the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med.
117(11):823-829.
w127. Trompet S, van Vliet P, de Craen AJ, et al (2010) Pravastatin and cognitive function in
the elderly. Results of the PROSPER study. J Neurol. 257(1):85-90.
w128. Feldman HH, Doody RS, Kivipelto M, et al (2010) Randomized controlled trial of
atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 74(12):956-964.
w129. Zhou B, Teramukai S, Fukushima M (2007) Prevention and treatment of dementia or
Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord. 23(3):194-201.
w130. Benito-León J, Louis ED, Vega S, Bermejo-Pareja F (2010) Statins and cognitive
functioning in the elderly: a population-based study. J Alzheimers Dis. 21(1):95-102.
w131. Zamrini E, McGwin G, Roseman JM (2004) Association between statin use and
Alzheimer's disease. Neuroepidemiology. 23(1-2):94-98.
w132. Bettermann K, Arnold AM, Williamson J, et al (2012) Statins, risk of dementia, and
cognitive function: secondary analysis of the ginkgo evaluation of memory study. J Stroke
Cerebrovasc Dis. 21(6):436-444.
w133. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, et al (2011) Statins and serum
cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol
Community Health. 65(11):949-957.
w134. Zandi PP, Sparks DL, Khachaturian AS, et al (2005) Do statins reduce risk of incident
dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry. 62(2):217224.
w135. Rea TD, Breitner JC, Psaty BM, et al (2005). Statin use and the risk of incident
dementia: the Cardiovascular Health Study. Arch Neurol 62:1047–1051.
w136. Li G, Higdon R, Kukull WA, et al (2004). Statin therapy and risk of dementia in the
elderly: a community-based prospective cohort study. Neurology 63:1624–1628.
w137. Rockwood K, Kirkland S, Hogan DB, et al (2002). Use of lipid-lowering agents,
indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol
59:223–227.
w138. Rodriguez EG, Dodge HH, Birzescu MA, et al (2002). Use of lipid-lowering drugs in
older adults with and without dementia: a community-based epidemiological study. J Am
Geriatr Soc 50:1852–1856.
w139. Jick H, Zornberg GL, Jick SS, et al: Statins and the risk of dementia. Lancet
2000;356:1627–1631.
w140. Van Der Maarel-Wierink CD, Vanobbergen JN, Bronkhorst EM, Schols JM, De Baat C
(2001) Risk factors for aspiration pneumonia in frail older people: a systematic literature
review. J Am Med Dir Assoc. 12(5):344-354.
w141. Canani RB, Cirillo P, Roggero P, et al (2006) Therapy with gastric acidity inhibitors
increases the risk of acute gastroenteritis and community acquired pneumonia in children.
Pediatrics. 117(5):e817-e820.
w142. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS (2011) Use of acidsuppressive
drugs and risk of pneumonia: a systematic review and meta-analysis. Can Med Assoc J.
183(3):310-319.
w143. Giulianio C, Wilhelm SM, Kale-Pradhan PB (2012) Are proton pump inhibitors
associated with the development of community-acquired pneumonia?: a meta-analysis. Expert
Rev Clin Pharmacol. 5(3):337-344.
w144. Johnstone J, Nerenberg K, Loeb M (2010) Meta-analysis: proton pump inhibitor use and
the risk of community-acquired pneumonia. Aliment Pharmacol Ther. 31(11):1165-1177.
w145. Estborn L, Joelson S (2008) Occurrence of community-acquired respiratory tract
infection in patients receiving esomeprazole: retrospective analysis of adverse events in 31
clinical trials. Drug Saf. 31:627-636.
w146. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J (2007) Use of
proton pump inhibitors and the risk of community-acquired pneumonia: a population-based
case-control study. Arch Intern Med. 167(9):950-955.
w147. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB (2004)
Risk of community acquired pneumonia and use of gastric acid suppressive drugs. J Am Med
Assoc. 292(16): 1955-1960.
w148. Marciniak C, Korutz AW, Lin E, Roth E, Welty L, Lovell L (2009) Examination of
selected clinical factors and medication use as risk factors for pneumonia during stroke
rehabilitation: a case-control study. Am J Phys Med Rehabil. 88(1):30-38.
w149. Meijvis SC, Cornips MC, Voorn GP, et al (2011) Microbial evaluation of proton-pump
inhibitors and the risk of pneumonia. Eur Respir J. 38(5):1165-1172.
w150. Myles PR, Hubbard RB, Mckeever TM, Pogson Z, Smith CJ, Gibson JE (2009) Risk of
community-acquired pneumonia and the use of statins, ace inhibitors and gastric acid
suppressants: a population-based case-control study. Pharmacoepidemiol Drug Saf. 18(4):269275.
w151. Rodriguez LA, Ruigomez A, Wallander MA, Johansson S (2009) Acid suppressive
drugs and community-acquired pneumonia. Epidemiology. 20(6):800-806.
w152. Sarkar M, Hennessy S, Yang YX (2008) Proton-pump inhibitor use and the risk for
community-acquired pneumonia. Ann Intern Med. 149(6):391-398.
w153. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER (2009) Acid-suppressive medication
use and the risk for hospital-acquired pneumonia. J Am Med Assoc. 301(20):2120-2128.
w154. Roughead EE, Ramsay EN, Pratt NL, Ryan P, Gilbert AL (2009) Proton pump
inhibitors and the risk of antibiotic use and hospitalisation for pneumonia. Med J Aust.
190(3):114-116.
w155. Laheij R, De Jager P, Gemen E, et al (2011) Gastric acid suppressive therapy and
community-acquired pneumonia, etiology and outcome. Gastroenterology 140(5),Suppl 1: S391
w156. Miano TA, Reichert MG, Houle TT, Macgregor DA, Kincaid EH, Bowton DL (2009)
Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs
ranitidine in cardiothoracic surgery patients. Chest. 136(2):440-447.
w157. Kasuya Y, Hargett JL, Lenhardt R, et al (2011) Ventilator associated pneumonia in
critically ill stroke patients: frequency, risk factors, and outcomes. J Crit Care. 26(2):273-279.
w158. Dublin S, Walker RL, Jackson ML, Nelson JC, Weiss NS, Jackson LA (2010) Use of
proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a populationbased case-control study. Pharmacoepidemiol Drug Saf. 19(8):792-802.
w159. Eurich DT, Sadowski CA, Simpson SH, Marrie TJ, Majumdar SR (2010) Recurrent
community-acquired pneumonia in patients starting acid-suppressing drugs. Am J Med.
123(1):47-53.
w160. Gau JT, Acharya U, Khan S, Heh V, Mody L, Kao TC (2010) Pharmacotherapy and the
risk for community-acquired pneumonia. BMC Geriatr. doi:10.1186/1471-2318-10-45.
w161. Beaulieu M, Williamson D, Sirois C, Lachaine J (2008) Do proton-pump inhibitors
increase the risk for nosocomial pneumonia in a medical intensive care unit?. J Crit Care.
23(4):513-518.
w162. Mallow S, Rebuck JA, Osler T, Ahern J, Healey MA, Rogers FB (2004) Do proton
pump inhibitors increase the incidence of nosocomial pneumonia and related infectious
complications when compared with histamine-2 receptor antagonists in critically ill trauma
patients?. Curr Surg. 61(5):452-458.
w163. Redelmeier DA, Mcalister FA, Kandel CE, Lu H, Daneman N (2010) Postoperative
pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ.
doi:10.1136/bmj.c2608
w164. Myles PR, Hubbard RB, Gibson JE, Pogson Z, Smith CJ, Mckeever TM (2009) The
impact of statins, ACE inhibitors and gastric acid suppressants on pneumonia mortality in a UK
general practice population cohort. Pharmacoepidemiol Drug Saf. 18(8):697-703.